Overcoming the challenges of tissue delivery for oligonucleotide therapeutics

内吞循环 寡核苷酸 内体 细胞生物学 核糖核酸 内化 生物 细胞 DNA 化学 基因 内吞作用 生物化学
作者
Tufan Gökirmak,Mehran Nikan,Svenja Wiechmann,Thazha P. Prakash,Michael Tanowitz,Punit P. Seth
出处
期刊:Trends in Pharmacological Sciences [Elsevier BV]
卷期号:42 (7): 588-604 被引量:61
标识
DOI:10.1016/j.tips.2021.04.010
摘要

Synthetic therapeutic oligonucleotides (STOs) target genes and gene products by utilizing endogenous endonucleases for the degradation of cellular RNA, RNA maturation pathways by modulating splicing, and protein translation by sterically blocking the access of ribosomal machinery to mRNA. STOs cross at least two phospholipid bilayers, plasma, and endosomal membranes, to reach their biological targets, mRNA and DNA inside cells. They enter the cell through receptor-mediated endocytic uptake and escape endosomal compartments to access the cytoplasm and/or nucleus, where they exert pharmacological effects through different antisense mechanisms. Backbone and sugar modifications improve the drug properties of STOs by increasing their metabolic stability and affinity for plasma proteins to reduce glomerular filtration and urinary excretion, thereby facilitating distribution to peripheral tissues. Subsequent interactions with cell surface proteins promotes cellular internalization by endocytic pathways. Next-generation oligonucleotide drugs are targeted therapeutics conjugated to endogenous or exogenous ligands for cell-surface receptors expressed in specific cell types or tissues. Givosiran (Givlaari®) is the first ligand conjugated STO developed by Alnylam for the treatment of adults with acute hepatic porphyria. Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing to exert their pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. In this review, we present the recent advances in this field with a specific focus on antisense oligonucleotides (ASOs) and siRNA therapeutics. Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing to exert their pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. In this review, we present the recent advances in this field with a specific focus on antisense oligonucleotides (ASOs) and siRNA therapeutics. chemically modified, short, single-stranded oligonucleotides (typically 12–20 mer) that bind to their target RNA by Watson-Crick base-pairing principles and modulate expression of their target mRNA by multiple antisense mechanisms. routes of drug administration where the compound is directly delivered into the tissue of interest. These methods of administration bypass tissue barriers such as the blood–brain barrier (BBB) and blood–retinal barrier and reduce exposure to systemic tissues. Examples of local delivery methods include intrathecal or intraocular injections for delivery to the CNS or the eye, and aerosol delivery to the lungs. an endonuclease that specifically cleaves the RNA strand of a DNA–RNA hybrid. ASOs bind to target mRNA through complementary base pairing, recruiting RNaseH1 that leads to degradation of the target mRNA, thus preventing the translation of mRNA into protein. an siRNA or miRNA-directed endonuclease that is composed of multiprotein complex, which incorporates one strand of a siRNA or miRNA duplex for interaction with complementary mRNA sequence. Upon activation, one of the proteins in the complex (Argonaute 2), cleaves the target mRNA. double-stranded short RNA or modified duplexes that mediate targeted mRNA degradation through RISC complex formation. routes of drug administration where the compound is directly delivered into the blood stream to access tissues. Systemic delivery methods for synthetic therapeutic oligonucleotides (STO) include intravenous, intramuscular, and subcutaneous injections.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
江璃完成签到,获得积分10
刚刚
TT发布了新的文献求助10
刚刚
美梦成真完成签到,获得积分10
1秒前
Gakay完成签到,获得积分10
1秒前
量子星尘发布了新的文献求助10
2秒前
szj完成签到,获得积分0
3秒前
旦皋完成签到,获得积分10
3秒前
赘婿应助花壳在逃野猪采纳,获得10
4秒前
卷卷完成签到,获得积分10
6秒前
JSY完成签到 ,获得积分20
6秒前
xyh完成签到,获得积分10
7秒前
小曾应助Florencia采纳,获得10
8秒前
神外王001完成签到 ,获得积分10
8秒前
13秒前
你是谁完成签到,获得积分10
14秒前
majf完成签到,获得积分10
15秒前
linhanwenzhou完成签到,获得积分10
15秒前
JSY关注了科研通微信公众号
15秒前
853225598完成签到,获得积分10
15秒前
798完成签到,获得积分10
16秒前
善学以致用应助董怼怼采纳,获得10
16秒前
妍儿完成签到,获得积分20
17秒前
隐形曼青应助高大的水壶采纳,获得10
17秒前
马哥二弟无敌完成签到 ,获得积分10
18秒前
19秒前
Florencia完成签到,获得积分10
19秒前
务实颜完成签到 ,获得积分10
19秒前
19秒前
amberzyc应助小远采纳,获得10
20秒前
20秒前
21秒前
21秒前
22秒前
22秒前
Rondab应助小猪采纳,获得30
22秒前
DLDL完成签到,获得积分10
22秒前
23秒前
沧海云完成签到 ,获得积分10
23秒前
发嗲的迎天完成签到 ,获得积分10
24秒前
hahaha发布了新的文献求助10
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029